



Fri Nov 09, 2018 10:34

Login Login name Password [Forgot password?](#) [Member's Privilege](#)

Quamnet VIP [Eng](#) | [繁](#) | [简](#)

[HOME](#) [NEWS](#) [MARKETS](#) [QUOTES](#) [FOREX](#) [QUAM RESEARCH](#) [E-GAZETTE](#)



QUOTE SEARCH

Symbol Lookup

WARRANT SEARCH

Advanced Search



Hot news

[China Concept](#)

[IPO](#)

[Commercial News](#)

[Media Outreach](#)

[ACN Newswire](#)

FEATURES:

[Oceanwide IR](#)

[Gazette](#)

[Learning](#)

[Newsletter](#)

[Info Center](#)



News > Article

Change font size:

Cedrus Investments' Head of Life Sciences Ms. Kimberly Nearing invited to speak at LIFE SCIENCES SUMMIT IN NEW YORK CITY

05 Nov 2018
PR Newswire Asia

HONG KONG, Nov. 5, 2018 /PRNewswire/ – Ms. Kimberly Nearing, the **Managing Director, Head of Life Sciences** at Cedrus Investments ("Cedrus"), was invited to speak on a panel at the **Life Sciences Summit** held on 25th October at the Time Warner Center in New York City.



The Life Sciences Summit is an investor and business development conference focusing on emerging companies and academic innovators. The objective of the event is to connect biotech innovators with potential financiers and industry partners they will need to move new discoveries into clinical development. Participants included: a Partner, **Third Rock Ventures**; Senior Director Business Development, **AstraZeneca**; Executive Director, **Merck**; a MD from the **Memorial Sloan-Kettering Cancer Center**; Oncology External Innovation, **Eli Lilly**; a Partner, **Venrock**; Senior Advisor, **Aisling Capital**; Managing Director, **Evercore**; a Partner, **Canaan Partners**; and Principal, **Merck Ventures**.

Ms. Nearing participated in the **Cross-border Investment and Partnering Opportunities** panel. Ms. Nearing's fellow panelist included: Dr. Michael Baran, PhD, MBA, Principal, **Pfizer Ventures** and Executive Director, External Science & Innovation, Oncology Research, Worldwide R&D, **Pfizer, Inc.**, Dr. Xiaodong (Eric) Wu, International Business Development Manager, **Qilu Pharmaceutical**, and Dr. Yan Zhang, PhD, Investment Director, **Cowin Capital**. The panel engaged in lively discussion about the following: 1) What Chinese investors and companies are looking for? 2) How do Chinese investors negotiate for value of early-stage life sciences companies? 3) What are the key challenges in conducting cross-border deals/partner search and how to avoid them?

Ms. Diane Fabel, Director of Operations, Center for Biotechnology & Long Island Bioscience Hub, Executive Director, Life Sciences Summit, said, "As Head of Life Sciences at Cedrus Investments, Ms. Nearing brings a wealth of expertise and insight into US/China cross-border investments and strategic partnerships. Her more than 20 years of experience in the life sciences industry, coupled with extensive transaction based experience in raising capital and fostering strategic alliances at the highest levels, contributed significant value to the plenary discussion and our Life Sciences Summit delegates."

About Cedrus Investments

Cedrus Investments is a global boutique investment firm headquartered in Hong Kong, specializing in Asset Management and Financial Advisory Services. Cedrus has extensive experience and a global network in the life sciences industry together with cross-border transactions in geographies including China, Australia, Asia, U.S., and Europe.

Media Enquiry:
Cedrus Investments Ltd.
Amy Sin
+852-3519-2828
information@cedrusinvestments.com

Logo - <http://photos.pmasia.com/pmh/20150930/8521506461LOGO>

Related Links :

<http://www.cedrusinvestments.com/index.html>

© Copyright Quamnet. All rights reserved. Republish the contents in whole or in part other than the authorized methods below, Quamnet reserves the right to proceed legal action.



Share : [Facebook](#) [LinkedIn](#) [Pinterest](#) [Reddit](#) [Forward to a friend](#)

Latest News:

- Luxey Int'l (08041) Q1 loss increases to \$14.25M 10:26
- Ali Pictures (01060) 1H loss reduced to RMB126M 10:23
- Grand T G Gold (08299) sinks into red, 1H loss \$13.7M 10:20
- EJE Holdings (08101) 1H loss shrinks to \$6M 10:18
- Ping An Good Doctor, UMP and Zheng He Announce Strategic Cooperation 10:17
- Mi Ming Mart (08473) 1H profit \$11M, up 89%; div \$0.009 10:15
- Ying Kee Tea (08241) halted for 1H results 10:09
- Elegance Print (08391) 1H loss increases to \$2.84M 10:06
- Vistar Holdings (08535) back to black; 1H profit \$14.8M 10:04

Market Update

[HK](#) [IDX FUT](#) [CN/ASIA](#) [WORLD](#) [More Indices >](#)



Watch List

Check your watch list and portfolio now

Quamnet Research

- Quammentary: Smartphone industry & AAC Tech (2018) 08 Nov 2018 [\\$](#)
- Performance from tech-related assets that were listed in 4Q17 08 Nov 2018 [\\$](#)
- First Comment: Wynn Macao's (1128) parent company warns about 4Q18 business outlook 08 Nov 2018 [\\$](#)
- US hostile stance towards China unlikely to change even Democrats regain power 07 Nov 2018 [\\$](#)
- Quammentary: Inline US mid-term election results, Hang Seng Index 07 Nov 2018 [\\$](#)